The Philippines will resume AstraZeneca COVID-19 vaccine use after evaluation, according to DOH.
The Department of Health (DOH) said that the Philippines will resume the use of AstraZeneca COVID-19 vaccine after a two-week evaluation.
In a televised briefing, DOH Undersecretary Maria Rosario Vergeire said that the evaluation of the experts with the Food and Drug Administration (FDA) had completed and they really said that they’ll again resume the vaccination with AstraZeneza COVID-19 vaccine when the evaluation came out after two weeks.
However, Vergeire noted that there Were “specific indications” to be put in place this time.
“Tapos na po yung pag-evaluate ng mga eksperto with FDA, at nagsabi naman sila talaga that after this two weeks, when the evaluation comes out, we will again resume the vaccination with AstraZeneza. Ibig sabihin meron tayong mga kailangan na guidance sa mga gagamit for these AstraZeneca vaccines at pinag-uusapan na yan ngayon,” Vergeire said.
Vergeire added that the Department of Health will consult with the National Immunization Technical Advisory Group (NITAG) and experts on how to impose the protocols before handing it out to the implementing units.
Vergeire’s statement came after the Food and Drug Administration (FDA) had recommended to continue the use of AstraZeneca COVID-19 vaccines on persons below 60 years old, saying that the benefit outweighed the risks.
The Philippines had temporarily suspended the use of AstraZeneca COVID-19 vaccine doses following reports of “very rare” blood clotting in persons vaccinated with the vaccine overseas.
What can you say about this? Let us know in the comments below.